Savara (NASDAQ:SVRA) Posts Quarterly Earnings Results, Hits Expectations

Savara (NASDAQ:SVRA) issued its earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11), Zacks reports.

Savara Price Performance

NASDAQ SVRA traded down $0.36 during mid-day trading on Wednesday, hitting $3.47. The stock had a trading volume of 2,023,397 shares, compared to its average volume of 1,206,000. The company has a 50 day simple moving average of $3.96 and a 200 day simple moving average of $4.22. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The company has a market cap of $571.16 million, a price-to-earnings ratio of -8.24 and a beta of 1.02. Savara has a 52-week low of $3.28 and a 52-week high of $5.70.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Evercore ISI reiterated an “in-line” rating and set a $5.00 target price (down previously from $7.00) on shares of Savara in a research report on Wednesday. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. Finally, HC Wainwright reduced their target price on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.